Cross-reactivity measures the extent to which different antigens appear similar to the immune system. The molecular determinants of specificity and cross-reactivity define the nature of antigenic variation and the selective processes that shape the distribution of …

In immunology, cross-reactivity has a more narrow meaning of the reaction between an antibody and an antigen that differs from the immunogen. It is sometimes also referred to as cross-immunity or cross-protective immunity, [2] although cross-reactivity does not necessarily confer cross-protection.

Percentages of antibody cross-reactivity. Percentages of antibody cross-reactivity in 2002 (a) and in 2007 (b).In 2002, antibodies against A/Wisconsin/67/05 were set to be 100% and the anti-A/Panama/2007/99 were compared to them, while in 2007, the A/Panama/2007/99 antibodies were set to be 100% and were compared with the A/Wisconsin/67/05 antibodies. * <0.0001 using Chi …

Cross-adsorbed secondary antibodies are polyclonal antibodies that are manufactured with an additional purification step to filter out members that bind to off-target species of immunoglobulin (IgG). The process decreases species cross-reactivity and increases specificity.

Cross-reactivity in adaptive immunity refers to the ability of immune cells to recognize and respond to similar but distinct antigens. This phenomenon, while aiding in the recognition and defense against diverse pathogens, can also lead to unintended immune responses, including autoimmune reactions.

Cross-reactivity occurs when the antibody binds to a molecule that is not the target substrate, resulting in a positive signal. Cross-reactivity is an attribute of the antibody (or antibodies) used in the immunoassay and is therefore assay and brand specific.

By focusing on the nature of antibodies, cross-reactivity in general, and antibody–antigen interactions, this review aims to characterize the nature of potential cross-reactive immune reactions between infectious non-self and self-tissue antigens which may be associated with autoimmunity but may not actually be the cause of disease onset.

Tissue cross-reactivity (TCR) studies for the development of therapeutic antibodies are conducted to estimate any possible binding sites within the human body that can be affected by the antibody when assessing safety in humans.

2025年2月11日 · Although the basis of cross-reactivity between O3 and O5 serotypes has been studied using monoclonal antibodies, 35, 36 a novel finding from our study is the observation of cross-reactivity between the O1v1 and O1v2 subtypes and between O2v1 and O2v2 subtypes, differing only by the addition of a single galactopyranose in the v2 genotypes, which ...

2022年3月17日 · Cross-reactivity across species is common among human antigen-derived antibodies but is not always a negative quality. For example, cross-reactivity can allow the same antibody to be used...